Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Brain Metastases, Adult
Interventions: DRUG: Olaparib|RADIATION: Stereotactic Radiosurgery|DRUG: Durvalumab|DRUG: Physicians Choice systemic chemotherapy
Sponsor: Colette Shen
Collaborators: AstraZeneca|University of North Carolina, Chapel Hill